HD 1, Deutsche Hodkin Studiengruppe

Stadium

mittleres Risiko

Fragestellung

Dosis des Extened Field

Ergebnis

Nach 20Gy EF-RT vergleichbare Rezidivraten.

Random

2 x (COPP + ABVD) + 40Gy EF-RT

2 x (COPP + ABVD) + 20Gy EF-RT, 40 Gy Bulk

Quellen

1.) Loeffler M, et al.:
Dose-response relationship of complimentary radiotherapy following four cycles of combination chemotherapy in intermediate - stage Hodgkin's disease.
JCO 15(1997):2275-2287

2.) Diehl V, Pfreundschuh M, Loeffler M, et al:
Chemotherapy of Hodgkin’s lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastin, and dacarbazine): Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
Med Oncol Tumor Pharmacother 6(1989):155-162